POINT-Logo-Colour (blue).png
POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common Stock
September 16, 2022 16:30 ET | POINT Biopharma
INDIANAPOLIS, Sept. 16, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT-Logo-Colour (blue).png
POINT Biopharma Prices Public Offering of Common Stock
September 13, 2022 21:47 ET | POINT Biopharma
INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT-Logo-Colour (blue).png
POINT Biopharma Announces Proposed Public Offering of Common Stock
September 13, 2022 16:05 ET | POINT Biopharma
INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT-Logo-Colour (blue).png
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
September 10, 2022 03:05 ET | POINT Biopharma
Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: A median rPFS time of 11.5 months A best radiographic objective response (CR, PR)...
POINT-Logo-Colour (blue).png
POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
September 04, 2022 18:10 ET | POINT Biopharma
INDIANAPOLIS, Sept. 04, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT-Logo-Colour (blue).png
POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
August 18, 2022 16:30 ET | POINT Biopharma
In advance of the abstract publication, POINT hosted an educational webinar entitled “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm” Watch the replay at...
POINT-Logo-Colour (blue).png
POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights
August 12, 2022 08:30 ET | POINT Biopharma
Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha targeted program, enters...
POINT-Logo-Colour (blue).png
POINT Biopharma to Host Investor Education Event, “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”, on August 18, 2022
August 08, 2022 08:30 ET | POINT Biopharma
The event will prepare investors for the release of SPLASH’s lead-in cohort efficacy data later this year by providing an overview of SPLASH’s trial design. Register online today at...
POINT-Logo-Colour (blue).png
POINT Biopharma to Participate in Upcoming Investor Conferences
July 06, 2022 08:30 ET | POINT Biopharma
INDIANAPOLIS, July 06, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT-Logo-Colour (1).png
POINT Biopharma announces appointment of Chris Horvath as EVP, Commercial
June 21, 2022 08:30 ET | POINT Biopharma
Mr. Horvath will lead the commercialization of POINT’s pipeline. He brings over a decade of experience in pharmaceutical commercialization, most recently as the VP and Head of Prostate Cancer...